Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about APRE, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Eprenetapopt (APR-246) | MDS | Phase 3 · NCT03745716 | Completed |
| ATR Inhibitor ATRN-119 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Phase 1/2 · NCT07578467 | Not yet recruiting |
| Pegylated Liposomal Doxorubicin Hydrochloride | Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With… | Phase 1/2 · NCT02098343 | Completed |
| Wee1 Inhibitor APR-1051 | Advanced Solid Tumor | Phase 1 · NCT06260514 | Recruiting |
| p53 Mutant Reactivator APR-548 | MDS | Phase 1 · NCT04638309 | Terminated |
Also used in these trials (approved or third-party drugs, not APRE's own candidates): Azacitidine, Dabrafenib, Decitabine, Venetoclax.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
APRE holds $37.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.5M/quarter from operations, an estimated runway of 32.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 40 · Elevated
Based on its current operating plan, the Company believes that its September 30, 2026 cash balance of approximately $ 37.8 million will be sufficient to fund the Company’s operating expenses and capital expenditure requirements into the first quarter of 2028.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when APRE files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Vestal Point Capital, LP | Institution (13G, 5%+) | 22,654,832 | 159.64% | 2026-03-31 |
| Squadron Master Fund LP | 5%+ holder (13G) | 1,271,081 | 8.96% | 2026-03-30 |
| Orin Hirschman | Institution (13G, 5%+) | 1,186,294 | 8.36% | 2026-03-31 |
| Oren Gilad President/CEO, Director · +178,618 options |
Insider | 395,695 | 2.79% | 2026-03-12 |
| Marc Duey Director · +38,199 options |
Insider | 259,892 | 1.83% | 2026-06-16 |
| Bernd R. Seizinger Director · +20,925 options |
Insider | 48,910 | 0.34% | 2026-06-16 |
| John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr · +126,496 options |
Insider | 43,528 | 0.31% | 2026-03-12 |
| Rifat Pamukcu Director · +20,925 options |
Insider | 22,689 | 0.16% | 2026-06-16 |
| John B Iii Henneman Director · +16,740 options |
Insider | 13,364 | 0.09% | 2026-06-16 |
| Richard Peters Director · +268,755 options |
Insider | 6,254 | 0.04% | 2026-06-16 |
| Michael Grissinger Director · +16,740 options |
Insider | 6,024 | 0.04% | 2026-06-16 |
| Gabriela Gruia Director · +16,740 options |
Insider | 4,180 | 0.03% | 2026-06-16 |
Share count 14,191,136 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for APRE and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →